Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 2/3 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 7Endocrine 7Thoracic 2Sarcoma 1NET 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 456Pancreatic Neoplasms 363Stomach Neoplasms 246Carcinoma, Hepatocellular 231Carcinoma, Non-Small-Cell Lung 164Colonic Neoplasms 145Esophageal Neoplasms 133Neoplasms 115Neoplasm Metastasis 114Ovarian Neoplasms 111Rectal Neoplasms 106Liver Neoplasms 101Breast Neoplasms 99Lung Neoplasms 78Melanoma 76Squamous Cell Carcinoma of Head and Neck 70Gastrointestinal Neoplasms 58Endometrial Neoplasms 58Carcinoma, Renal Cell 54Uterine Cervical Neoplasms 52Cholangiocarcinoma 52Biliary Tract Neoplasms 52Triple Negative Breast Neoplasms 49Head and Neck Neoplasms 48Sarcoma 46Prostatic Neoplasms 45Esophageal Squamous Cell Carcinoma 39Urinary Bladder Neoplasms 34Small Cell Lung Carcinoma 31Carcinoma 29

Interventions

tislelizumab 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Carcinoma, Anaplastic × Gastrointestinal × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡